Sumana Gangi, MD
Endocrinology, Diabetes & Metabolism · Mesquite, TXNPI 1487679213
Payments from drug & device makers
Across 2,036 payments — averaging $6462.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$10.3M
- Amgen$1.3M
- AbbVie$439K
- Lilly USA, LLC$381K
- Novo Nordisk$225K
- Sanofi US Services Inc.$214K
- plus $252K from 54 others
Across 43 payments — averaging $8155.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$207K
- Amgen$143K
- AbbVie$762
What the payments were for
- Consulting fees$49,0126%
- Speaking & faculty fees$653,44383%
- Travel & lodging$59,9518%
- Food & beverage$24,4273%
- Education$510%
- Gifts$2380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$153,365
- TRULICITY$128,521
- RYBELSUS$114,023
- JARDIANCE$105,696
- Ozempic$58,336
- SOLIQUA 100/33$29,054
- FARXIGA$28,969
- STEGLATRO$27,303
- HUMULIN$24,814
- TOUJEO$24,444
- Tresiba$18,051
- Victoza$11,039
- AFREZZA$3,672
- Xultophy 100/3.6$1,866
- LANTUS$1,250
- CeQur Simplicity$646
- t:slim X2 insulin pump$250
- FreeStyle Libre 2$145
How this compares
$13,158,102 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 611 | $964,581 |
| MounjaroTirzepatide | 325 | $549,759 |
| JardianceEmpagliflozin | 325 | $412,698 |
| TrulicityDulaglutide | 216 | $336,569 |
| Tresiba Flextouch U-100Insulin Degludec | 259 | $233,880 |
| FarxigaDapagliflozin Propanediol | 220 | $201,050 |
| ProliaDenosumab | 77 | $135,741 |
| Teriparatide | 34 | $119,499 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $114,477 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $86,036 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $76,102 |
| Humulin R U-500Insulin Regular, Human | 20 | $75,038 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 59 | $71,139 |
| RybelsusSemaglutide | 49 | $68,111 |
| Xigduo XrDapaglifloz Propaned/Metformin | 62 | $66,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $225,065 | $1,077,582725 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $381,285 | $912,534608 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $53,237 | $472,302375 claims |
| AstraZenecaFarxiga | $30,335 | $201,050220 claims |
| AmgenProlia | $1,341,461 | $135,74177 claims |
| MerckJanuvia, Janumet, Janumet Xr | $56,756 | $68,27871 claims |
| BayerKerendia | $209 | $20,18123 claims |
| AbbVieSynthroid | $439,207 | $15,747191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Mesquite
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
- Amir HassanHouston$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.